X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (473) 473
Book Review (226) 226
Newspaper Article (33) 33
Publication (32) 32
Report (11) 11
Book Chapter (3) 3
Conference Proceeding (3) 3
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (333) 333
oncology (303) 303
humans (266) 266
ovarian cancer (266) 266
female (215) 215
olaparib maintenance therapy (205) 205
maintenance therapy (191) 191
cancer (163) 163
chemotherapy (162) 162
poly polymerase (142) 142
ovarian neoplasms - drug therapy (132) 132
mutation (121) 121
open-label (121) 121
homologous recombination (108) 108
olaparib (99) 99
double-blind (97) 97
care and treatment (89) 89
ovarian neoplasms - genetics (89) 89
breast cancer (88) 88
tumors (87) 87
dna repair (85) 85
parp inhibitors (81) 81
parp inhibitor (74) 74
antineoplastic agents - therapeutic use (73) 73
fallopian-tube (73) 73
cancer therapies (72) 72
patients (68) 68
middle aged (67) 67
obstetrics & gynecology (66) 66
research (65) 65
ovarian neoplasms - pathology (63) 63
poly polymerase inhibitors - therapeutic use (63) 63
breast-cancer (62) 62
clinical trials (61) 61
dna damage (61) 61
aged (60) 60
ovarian-cancer (60) 60
pharmacology & pharmacy (60) 60
analysis (59) 59
deoxyribonucleic acid--dna (59) 59
platinum (56) 56
animals (54) 54
genetic aspects (51) 51
health aspects (51) 51
bevacizumab (49) 49
adult (48) 48
pegylated liposomal doxorubicin (48) 48
review (48) 48
brca (47) 47
recurrent epithelial ovarian (47) 47
brca1 (46) 46
maintenance (46) 46
ribose (46) 46
monosaccharides (45) 45
sugars (45) 45
brca1 protein - genetics (44) 44
phthalazines - therapeutic use (44) 44
piperazines - therapeutic use (44) 44
survival (44) 44
pharmaceutical industry (43) 43
carcinoma (42) 42
epithelial ovarian (42) 42
brca1 protein (41) 41
drug therapy (41) 41
earnings per share (40) 40
health maintenance organizations--hmos (40) 40
brca2 protein - genetics (39) 39
carcinoma, ovarian epithelial (39) 39
hematology, oncology and palliative medicine (39) 39
molecular targeted therapy (39) 39
biomarkers (38) 38
genes, brca1 (38) 38
poly polymerase inhibitors - pharmacology (38) 38
primary peritoneal (37) 37
repair (37) 37
endocrine system diseases (36) 36
women (36) 36
dna-repair (35) 35
synthetic lethality (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
disease-free survival (34) 34
immunotherapy (34) 34
ovarian carcinoma (34) 34
parp (34) 34
stock exchanges (34) 34
brca2 mutations (33) 33
dividends (33) 33
genes, brca2 (33) 33
medical research (33) 33
negative breast-cancer (33) 33
somatic mutations (33) 33
polymerase (32) 32
brca mutation (31) 31
germ-line mutation (31) 31
poly polymerase inhibitors (31) 31
inhibitors (30) 30
mutations (30) 30
antineoplastic agents - pharmacology (29) 29
combination (29) 29
treatment outcome (29) 29
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1207 - 1214
Summary Background Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1,... 
Hematology, Oncology and Palliative Medicine | TRIAL | POLY(ADP-RIBOSE) POLYMERASE | ONCOLOGY | BEVACIZUMAB | DOWN-REGULATION | FALLOPIAN-TUBE | OPEN-LABEL | EPITHELIAL OVARIAN | MAINTENANCE THERAPY | PRIMARY PERITONEAL | NEGATIVE BREAST-CANCER | Piperazines - administration & dosage | Confidence Intervals | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Neoplasms, Glandular and Epithelial - mortality | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Ovarian Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Risk Assessment | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Carcinoma, Ovarian Epithelial | Aged | Women | Antimitotic agents | Relapse | Oncology, Experimental | Research | Antineoplastic agents | Vascular endothelial growth factor | Sugars | Cancer | Diseases | Monosaccharides | Ovarian cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2015, Volume 373, Issue 18, pp. 1697 - 1708
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 15, pp. 1382 - 1392
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2018, Volume 379, Issue 26, pp. 2495 - 2505
Journal Article
Journal Article
by Pujade-Lauraine, Eric and Ledermann, Jonathan and Ledermann, Jonathan A and Selle, Frédéric and Gebski, Val and Penson, Richard and Penson, Richard T and Oza, Amit M and Oza, Amit and Korach, Jacob and Huzarski, Tomasz and Poveda, Andrés and Pignata, Sandro and Friedlander, Michael and Colombo, Nicoletta and Harter, Philipp and Fujiwara, Keiichi and Ray-Coquard, Isabelle and Banerjee, Susana and Liu, Joyce and Lowe, Elizabeth S and Bloomfield, Ralph and Pautier, Patricia and Byrski, Tomasz and Scambia, Giovanni and Nicoletto, Maria and Nussey, Fiona and Clamp, Andrew and Poveda Velasco, Andrés and Rodrigues, Manuel and Lotz, Jean-Pierre and Provencher, Diane and Prat Aparicio, Aleix and Vidal Boixader, Laura and Scott, Clare and Tamura, Kenji and Yunokawa, Mayu and Lisyanskaya, Alla and Medioni, Jacques and Pécuchet, Nicolas and Dubot, Coraline and de la Motte Rouge, Thibault and Kaminsky, Marie-Christine and Weber, Béatrice and Lortholary, Alain and Parkinson, Christine and Williams, Sarah and Cosin, Jonathan and Hoffman, James and Plante, Marie and Covens, Allan and Sonke, Gabe and Joly, Florence and Floquet, Anne and Hirte, Holger and Amit, Amnon and Park-Simon, Tjoung-Won and Matsumoto, Koji and Tjulandin, Sergei and Kim, Jae Hoon and Kim, Byoung-Gie and Kim, Jae Weon and Gladieff, Laurence and Sabbatini, Roberto and O'Malley, David and Timmins, Patrick and Kredentser, Daniel and Laínez Milagro, Nuria and Barretina Ginesta, Maria Pilar and Tibau Martorell, Ariadna and Gómez de Liaño Lista, Alfonso and Ojeda González, Belén and Mileshkin, Linda and Mandai, Masaki and Boere, Ingrid and Ottevanger, Petronella and Nam, Joo-Hyun and Filho, Elias and Hamizi, Salima and Cognetti, Francesco and Warshal, David and Dickson-Michelson, Elizabeth and Kamelle, Scott and McKenzie, Nathalie and Rodriguez, Gustavo and Armstrong, Deborah and Chalas, Eva and Celano, Paul and Behbakht, Kian and Davidson, Susan and Welch, Stephen and Helpman, Limor and Fishman, Ami and Bruchim, Ilan and Sikorska, Magdalena and Słowińska, Anna and Rogowski, Wojciech and Bidziński, Mariusz and Śpiewankiewicz, Beata and Casado Herraez, Antonio and ... and SOLO2-ENGOT-Ov21 Investigators and SOLO2/ENGOT-Ov21 investigators
The Lancet Oncology, ISSN 1470-2045, 09/2017, Volume 18, Issue 9, pp. 1274 - 1284
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2019, Volume 381, Issue 4, pp. 317 - 327
Journal Article
ONCOTARGET, ISSN 1949-2553, 07/2017, Volume 8, Issue 27, pp. 43598 - 43599
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 852 - 861
Journal Article